Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06930521
What this trial is testing

JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year

Who this might be right for
Cardiovascular HealthBreast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)+4 more
Women's College Hospital 300
Not applicableApproved For MarketingNCT04100694
What this trial is testing

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Who this might be right for
NRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more
Merus B.V.
Large-scale testing (Phase 3)Not Yet RecruitingNCT07748260
What this trial is testing

De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast

Who this might be right for
HER2-positive Breast Cancer
Guangdong Provincial People's Hospital 592
Not applicableUnknownNCT03847818
What this trial is testing

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Shandong University 268
Early research (Phase 1)Study completedNCT05471648
What this trial is testing

A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers

Who this might be right for
Breast Cancer
EirGenix, Inc. 135
Not applicableActive Not RecruitingNCT03904173
What this trial is testing

Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsHormone Receptor Positive Tumor
Oslo University Hospital 2,300
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07565324
What this trial is testing

Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)

Who this might be right for
HER-2 Positive Breast Cancer
National Taiwan University Hospital 54
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07394946
What this trial is testing

Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.

Who this might be right for
Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer
Cancer Care Hospital & Research Centre Foundation, Lahore 126
Testing effectiveness (Phase 2)Study completedNCT02132949
What this trial is testing

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 401
Not applicableNot Yet RecruitingNCT07309887
What this trial is testing

This Clinical Trial is a Retrospective, Multicenter Cohort Study Evaluating the Real-world Characteristics and Risk of Disease Recurrence in Hormone Receptor-positive, HER2-negative Early Breast Cancer.

Who this might be right for
Early Breast Cancer
Samsung Medical Center 100,000
Early research (Phase 1)Study completedNCT02605915
What this trial is testing

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Who this might be right for
HER2-Positive Metastatic Breast CancerHER2-Negative Metastatic Breast CancerLocally Advanced or Early Breast Cancer
Hoffmann-La Roche 98
Testing effectiveness (Phase 2)UnknownNCT04717531
What this trial is testing

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 60
Not applicableEnded earlyNCT06126003
What this trial is testing

Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Who this might be right for
Breast Cancer
BioCorteX Inc 2
Testing effectiveness (Phase 2)Looking for participantsNCT07647263
What this trial is testing

Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
The First Affiliated Hospital of Soochow University 124
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Large-scale testing (Phase 3)UnknownNCT03926091
What this trial is testing

Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 2,172
Large-scale testing (Phase 3)Study completedNCT01940497
What this trial is testing

The Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 240
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07005882
What this trial is testing

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

Who this might be right for
Breast Cancer PatientsBreast Cancer Early Stage Breast Cancer (Stage 1-3)HR+/HER2- Breast Cancer+1 more
Azienda Ospedaliero-Universitaria Careggi 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT03917082
What this trial is testing

Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer

Who this might be right for
Breast Cancer FemaleHormone Receptor Positive Tumor
British Columbia Cancer Agency 290
Large-scale testing (Phase 3)Study completedNCT00553358
What this trial is testing

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 455
Next Page